Abstract 1600P
Background
Sarcopenia is a disorder that causes muscle mass and strength loss, which can result in diminished mobility and functional limits. Depression and a bad assessment of one's own health are common results among cancer patients. As a result, this study aimed to look at the association between sarcopenia, depression, and health perception.
Methods
Cancer patients were the subject of a retrospective study from January to April 2023. The study included 150 patients who had different forms of a verified cancer diagnosis. These individuals were admitted to Mayo Hospital's Palliative Care Cancer Department. The presence of depressive symptoms was assessed using the Patient Health Questionnaire (PHQ-9). SARC-F was used to measure all the five dimensions of sarcopenia. To examine self-perceived health, a self-report questionnaire was used. The relationships between sarcopenia, depression, and health perception were investigated using correlation analysis.
Results
We observed a significant and positive association between depression and the dimensions of sarcopenia. Specifically, we found a positive correlation between depression and SARC1=Strength (r = 0.378, p<0.01), SARC2=Assistance in walking (r = 0.390, p<0.01), SARC3=Rise from a chair (r = 0.488, p<0.01), and SARC4=Climb stairs (r = 0.392, p<0.01). However, we found a positive but insignificant relationship between depression and SARC5=Falls (r = 0.150, p>0.05). In addition, we discovered that patients' perception of poor health was correlated with depression (r = -0.391, p<0.01), SARC2=Assistance in walking (r = -0.235, p<0.01), SARC3=Rise from a chair (r = -0.259, p<0.01), and SARC4=Climb stairs (r = -0.277, p<0.01). However, we did not find a significant relationship between health perception and two dimensions of sarcopenia (i.e., SARC1=Strength and SARC5=Falls).
Conclusions
Sarcopenia adversely affects the physical and mental health of cancer patients. They feel depressed and perceive their health as bad which imparts a negative impact on the outcome of these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05